SUMMARY

OncologySTAT Editorial Team

Inhibitors of the vascular endothelial growth factor (VEGF), specifically the multi-target tyrosine kinase inhibitors (TKIs) sunitinib and sorafenib, have significantly advanced the treatment of metastatic renal cell carcinoma. However, most studies of these drugs have either excluded non–clear cell subtypes or included only a scant number of these less common histologies. This prospective phase II trial was performed in Korea to evaluate the benefit of sunitinib in patients with metastatic non–clear...